| HOME >> BIOLOGY >> TECHNOLOGY |
Challenges facing biotech drug development 27
Complicated disease targets 28
Escalating costs 28
Market dynamics 29
Competitive landscape 32
Chapter 3 Roche 34
Summary 34
Company overview 35
Sales performance analysis 35
Sales by drug class 36
Marketed products 37
Key brands analysis 38
Avastin (bevacizumab) 38
MabThera/Rituxan (rituximab) 40
Herceptin (trastuzumab) 41
R&D pipeline analysis 42
Profiles of key late-stage pipeline products 43
Oncology 43
Autoimmune and inflammatory disorders 44
Metabolic disorders 46
Growth Strategies 47
Expertise in mAb development and commercialization to allow continued domination 47
Line-extension studies on leading oncology products are expected to further expand Roche's market
48
Increasing focus on emerging markets in the Asia pacific region 49
Other products to contribute strongly to near-term growth 49
SWOT Analysis 50
Chapter 4 Amgen 51
Company overview 52
Sales performance analysis 52
Sales by therapeutic class 53
Marketed products 54
Key brands analysis 55
Neulasta (pegfilgrastim)/ Neupogen(filgrastim) 55
Enbrel (etanercept) 56
Epogen (erythropoietin Alfa) 56
Aranesp (darbepoetin alfa) 56
R&D pipeline analysis 57
Growth strategies 58
Expanding the range of indications for denosumab 58
Lifecycle management strategies on various product lines 58
Strategic acquisitions and licensing partnerships 59
SWOT analysis 62
Chapter 5 Gilead Sciences 63
Summary 63
Company Overview 64
Sales performance analysis 64
Sales by therapeutic class 65
Regional sales analysis 66
Marketed products 67
Key brands analysis 68
Atripla (tenofovir/emtricita
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |